You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,187,991

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,187,991

Title:	Transgenic animal models for type II diabetes mellitus
Abstract:	The generation of transgenic animal models for testing various treatments of Type II Diabetes Mellitus are described. The DNA construct allows pancreatic .beta. cell-specific expression of human islet associated polypeptide (IAPP) under the regulation of the rat insulin II promoter in both cell lines and transgenic animals. The DNA construct is introduced into animal embryos by microinjection as one or multiple copies or into established cell lines by electroporation. The transgenic animals develop amyloid plaque deposits in the islets of Langerhans in the pancreas, fasting hyperglycemia, glycouria and diabetic glomerulosclerosis at 3 to 5 months of age. The cell lines can be screened for treatments that inhibit expression of human IAPP; the transgenic animals can be screened for treatments that either enhance or inhibit the progression of this disease phenotype.
Inventor(s):	Soeller; Walter C. (Mystic, CT), Carty; Maynard D. (Gales Ferry, CT), Kreutter; David K. (Madison, CT)
Assignee:	Pfizer Inc (New York, NY)
Application Number:	08/446,935
Patent Claims:	1. A transgenic mouse whose somatic and germ cells contain a recombinant DNA sequence comprising in operable linkage, a rat insulin II promoter, a sequence encoding the human IAPP, a human albumin intron I sequence, a human GAPDH termination sequence and a human GAPDH polyadenylation sequence, wherein the expression of said recombinant DNA sequence results in a diabetic phenotype of fasting hyperglycemia. 2. The transgenic mouse according to claim 1, wherein said sequence encoding the human IAPP is genomic DNA. 3. The transgenic mouse according to claim 1, wherein said sequence encoding the human IAPP is cDNA.

Details for Patent 6,187,991

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.